# American Vanguard Corp: Form 10-Q for the period ended Jun 30, 2016

- Company: [American Vanguard Corp](/companies/avd.md) (CIK 5981)
- Form: 10-Q
- Filed: 2016-08-02
- Accepted by EDGAR: Aug 2, 2016, 16:01 ET
- Period: 2016-06-30
- Accession: 0001193125-16-668296
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/5981/000119312516668296/d211128d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/5981/000119312516668296/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-04-01 to 2016-06-30 | $72.7m | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2016-01-01 to 2016-06-30 | $142.2m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2016-04-01 to 2016-06-30 | $41.3m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2016-01-01 to 2016-06-30 | $83.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2016-04-01 to 2016-06-30 | $31.4m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2016-01-01 to 2016-06-30 | $58.9m | us-gaap:GrossProfit |
| Operating income | 3 months, 2016-04-01 to 2016-06-30 | $5.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2016-01-01 to 2016-06-30 | $9.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-04-01 to 2016-06-30 | $462.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2016-01-01 to 2016-06-30 | $1.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-04-01 to 2016-06-30 | $1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2016-01-01 to 2016-06-30 | $2.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-04-01 to 2016-06-30 | $3.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2016-01-01 to 2016-06-30 | $6.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-04-01 to 2016-06-30 | $0.11 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2016-01-01 to 2016-06-30 | $0.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-04-01 to 2016-06-30 | $0.11 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2016-01-01 to 2016-06-30 | $0.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-04-01 to 2016-06-30 | 29,377,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2016-01-01 to 2016-06-30 | 29,342,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2016-01-01 to 2016-06-30 | $25.5m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months, 2016-01-01 to 2016-06-30 | $224.0k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | at 2016-06-30 | $5.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-06-30 | $258.5m | us-gaap:AssetsCurrent |
| Total assets | at 2016-06-30 | $459.7m | us-gaap:Assets |
| Current liabilities | at 2016-06-30 | $104.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-06-30 | $184.8m | us-gaap:Liabilities |
| Long-term debt | at 2016-06-30 | $49.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2016-06-30 | $18.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2016-06-30 | $274.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 40,383 characters.

### FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

### RESULTS OF OPERATIONS

### Quarter Ended June 30:

| Net sales: | 2016 | 2015 | Change |
| --- | ---: | ---: | ---: |
| Insecticides | $30,912 | $27,586 | $3,326 |
| Herbicides/soil fumigants/fungicides | 21,093 | 17,451 | 3,642 |
| Other, including plant growth regulators | 6,331 | 12,755 | (6,424) |
| Total crop | 58,336 | 57,792 | 544 |
| Non-crop | 14,388 | 8,731 | 5,657 |
|  | $72,724 | $66,523 | $6,201 |
| Cost of sales: |  |  |  |
| Insecticides | $20,029 | $18,401 | $1,628 |
| Herbicides/soil fumigants/fungicides | 10,913 | 9,596 | 1,317 |
| Other, including plant growth regulators | 4,025 | 8,998 | (4,973) |
| Total crop | 34,967 | 36,995 | (2,028) |
| Non-crop | 6,362 | 4,407 | 1,955 |
|  | $41,329 | $41,402 | $(73) |
| Gross margin: |  |  |  |
| Insecticides | $10,883 | $9,185 | $1,698 |
| Herbicides/soil fumigants/fungicides | 10,180 | 7,855 | 2,325 |
| Other, including plant growth regulators | 2,306 | 3,757 | (1,451) |
| Gross margin crop | 23,369 | 20,797 | 2,572 |
| Gross margin non-crop | 8,026 | 4,324 | 3,702 |
|  | $31,395 | $25,121 | $6,274 |
| Gross margin crop | 40% | 36% |  |
| Gross margin non-crop | 56% | 49% |  |
| Total gross margin | 43% | 38% |  |

| Net sales: | 2016 | 2015 | Change |
| --- | ---: | ---: | ---: |
| US | $51,773 | $43,842 | $7,931 |
| International | 20,951 | 22,681 | (1,730) |
|  | $72,724 | $66,523 | $6,201 |

20

Financial performance for the quarter ended June 30, 2016 included sales of $72,724, which were up approximately 9%, as compared to sales of $66,523 for the second quarter of 2015. Our gross profit performance ended at $31,395 or 43% of sales, as compared to $25,121 or 38% of sales for the comparable quarter last year.

With respect to sales performance by category, sales for our Crop business were up approximately 1% at $58,336, as compared to $57,792 for the same period of the prior year, while sales for non-crop products were up 65% at $14,388, as compared to $8,731 last year. A more detailed discussion of general market conditions and sales performance by category of products appears below.

Second quarter 2016 financial performance was influenced by several factors, including reduced international toll manufacturing activity, and delayed sales of our cotton defoliant and our soil fumigant products. Notwithstanding those factors, we saw improved sales performance in our Insecticide product group, our Herbicide and Fungicide product lines and our pharmaceutical and Other Non-crop products.

Sales of our Insecticide group for crop applications were up 12%, to $30,912, as compared to $27,586 for the second quarter of 2015. Within this group, sales of our granular soil insecticides (“GSIs”) were up approximately 18%, as compared to the comparable quarter in 2015. Sales of our Thimet®, Aztec®, Mocap® and Nemacur® products were significantly higher, partially offset by reduced quarterly sales of our Counter insecticide as some international customers managed their working capital and inventories through drought conditions, particularly in South Africa. In our non-granular insecticide products, demand for our Bidrin® foliar insecticide, which is used primarily for plant and stink bug defense in cotton, declined with customer inventory management, causing some second quarter sales to be delayed until the third quarter.

Within the group of Herbicides/Fungicides/Fumigants, sales for the second quarter of 2016 increased by approximately 21% to $21,093, as compared to $17,451 in the same period of 2015. Sales of our herbicide products rose significantly on the strength of a 56% increase in sales of our post-emergent corn herbicide, Impact®, in part attributable to this year’s robust 94 million acre U.S. corn plantings and in part to reduced channel inventory. Sales of our Bromacil product line, acquired in mid second quarter of 2015, increased threefold. Sales of our soil fumigants were down in the quarter due to wet weather and delayed on-ground applications in the Southeast and Northwest sections of the U.S. We expect to recover these reduced spring sales as additional product is applied to the fields during the third and fourth quarters of 2016. With regard to our fungicide product line, during the second quarter of 2016 sales increased by 37%, as compared to the same period in 2015.

Within the group of Other products (which includes plant growth regulators, molluscicides and tolling activity), our sales declined about 50% to $6,331, as compared to $12,755 in the second quarter of 2015. There were two main drivers for this performance. First, toll manufacturing activity occurred later in the quarter (as compared to 2015); we expect to recognize sales on these products later in 2016. Second, a decline in purchases of our Folex® cotton defoliant occurred during the second quarter, as cotton growers chose to shift their procurement of this harvest aid to early third quarter, for defoliation use prior to the September/October harvest.

Our Non-crop sales ended the second quarter of 2016 at $14,388, which was 65% above sales of $8,731 for the same period of the prior year. During the quarter, we saw a significant increase in sales of both our pest strip products, which were up 72% as a result of customers having worked through excess inventory purchased in late 2014 and our pharmaceutical products, which recorded a threefold increase. Finally, our Envance majority owned subsidiary continued to earn revenues from a third party for licenses to certain of our natural oil products.

From a geographic perspective, our U.S. sales were up 18% and our International sales were down 8%. The decline in International sales was driven primarily by reduced sales of Counter, due to drought conditions affecting demand in South Africa and reduced tolling sales, caused by a manufacturing schedule change. We believe sales associated with that activity will be recognized later in the year. These declines were partially offset by strong performance of Nemacur and Bromacil, which we acquired in the second quarter of 2015.

Our cost of sales for the second quarter of 2016 was $41,329 or 57% of sales. This compared to $41,402 or 62% of sales for the same period of 2015. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales.

The raw materials element of our cost of sales decreased by about 1% this quarter, as compared to the same period of last year. The change was driven by the specific mix of sales and lower raw material purchase prices.

Our labor and burden costs remained well controlled and were 7% lower in the three months ended June 30, 2016, as compared to the same period of the prior year. Further, our factory activity increased as we reacted to much improved channel inventory levels of our products. As a result, associated factory cost recovery increased by 9%, as compared to the second quarter of 2015. These improvements resulted in lower unabsorbed factory overhead costs, which amounted to 3% of sales in the second quarter of 2016, as compared to 6% in the same quarter of 2015, and added $1,404 to our gross profit performance, as compared to this time last year.

It should be noted that, when making comparisons with other companies’ financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

Operating expenses increased by $2,379 to $26,301 for the three months ended June 30, 2016, as compared to the same period in 2015. The differences in operating expenses by department are as follows:

|  | 2016 | 2015 | Change |
| --- | ---: | ---: | ---: |
| Selling | $6,464 | $6,934 | $(470) |
| General and administrative | 8,389 | 7,069 | 1,320 |
| Research, product development and regulatory | 6,165 | 5,275 | 890 |
| Freight, delivery and warehousing | 5,283 | 4,644 | 639 |
|  | $26,301 | $23,922 | $2,379 |

- Selling expenses decreased $470 over the same quarter of the prior year. The main driver for the decrease is a reduction in advertising and promotional activities.
- General and administrative expenses increased by $1,320 to $8,389, as compared to $7,069 for the same period of the prior year. The main driver for the increase is related to increased incentive compensation, as a result of our improved financial performance.
- Research, product development costs and regulatory expenses increased by $890 to $6,165, as compared to the same period of the prior year. In the three months ended June 30, 2016, we increased our spending on regulatory compliance, field trials for product development and our SIMPAS development project.
- Freight, delivery and warehousing costs increased by $639 to $5,283, as compared to the same period of 2015. As a percentage of sales, freight costs were 7.2% of sales for the three months ended June 30, 2016, as compared to 7.0% for the same period of the prior year.

Interest costs, net of capitalized interest, were $462 in the three months ended June 30, 2016, as compared to $662 in the same period of 2015. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Q2 2016 Average Debt | Interest Expense | Interest Rate | Q2 2015 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Average revolving line of credit | $71,450 | $389 | 2.2% | $105,796 | $527 | 1.9% |
| Notes payable | 27 | — | — | 1,404 | 68 | — |
| Interest income | — | (1) | — | — | (1) | — |
| Amortization of deferred loan fees | — | 63 | — | — | 60 | — |
| Amortization of other deferred liabilities | — | 9 | — | — | 38 | — |
| Other interest expense | — | 11 | — | — | 18 | — |
| Subtotal | $71,477 | $471 | 2.6% | $107,200 | $710 | 2.6% |
| Capitalized interest | — | (9) | — | — | (48) | — |
| Total | $71,477 | $462 | 2.6% | $107,200 | $662 | 2.5% |

22

The Company’s average overall debt for the three months ended June 30, 2016 was $71,477, as compared to $107,200 for the three months ended June 30, 2015. During the quarter we have continued to work down our revolving debt. As can be seen from the table above, our effective bank interest rate was 2.6% for the three months ended June 30, 2016, which was essentially flat when compared to an effective rate of 2.5% for the comparable three month period of the prior year.

Income tax expense was $1,203 for the three months ended June 30, 2016, as compared to a benefit of $393 for the comparable period in 2015. The effective tax rate for the quarter was 26.0% (which was a tax expense), as compared to 73.2% (which was a tax benefit) in the same period of the prior year. The change in effective tax rate is primarily driven by improved year on year financial performance in jurisdictions with higher tax rates.

Furthermore, the effective tax rate for the three months ended June 30, 2016 is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

Our net income for the second quarter of 2016 was $3,246 or $0.11 per basic and diluted share, as compared to $781 or $0.03 per basic and diluted share in the same quarter of 2015.

### Six Months Ended June 30:

| Net sales: | 2016 | 2015 | Change |
| --- | ---: | ---: | ---: |
| Insecticides | $64,018 | $61,945 | $2,073 |
| Herbicides/soil fumigants/fungicides | 45,767 | 39,291 | 6,476 |
| Other, including plant growth regulators | 9,820 | 16,077 | (6,257) |
| Total crop | 119,605 | 117,313 | 2,292 |
| Non-crop | 22,593 | 15,775 | 6,818 |
|  | $142,198 | $133,088 | $9,110 |
| Cost of sales: |  |  |  |
| Insecticides | $42,215 | $41,005 | $1,210 |
| Herbicides/soil fumigants/fungicides | 24,761 | 23,186 | 1,575 |
| Other, including plant growth regulators | 5,575 | 10,367 | (4,792) |
| Total crop | 72,551 | 74,558 | (2,007) |
| Non-crop | 10,749 | 8,759 | 1,990 |
|  | $83,300 | $83,317 | $(17) |
| Gross margin: |  |  |  |
| Insecticides | $21,803 | $20,940 | $863 |
| Herbicides/soil fumigants/fungicides | 21,006 | 16,105 | 4,901 |
| Other, including plant growth regulators | 4,245 | 5,710 | (1,465) |
| Gross margin crop | 47,054 | 42,755 | 4,299 |
| Gross margin non-crop | 11,844 | 7,016 | 4,828 |
|  | $58,898 | $49,771 | $9,127 |
| Gross margin crop | 39% | 36% |  |
| Gross margin non-crop | 52% | 44% |  |
| Total gross margin | 41% | 37% |  |

| Net sales: | 2016 | 2015 | Change |
| --- | ---: | ---: | ---: |
| US | $101,628 | $93,064 | $8,564 |
| International | 40,570 | 40,024 | 546 |
|  | $142,198 | $133,088 | $9,110 |

23

Overall financial performance including sales and net income for the six month period ended June 30, 2016 showed improvement, as compared to the same period in 2015. Sales for the period were up approximately 7% to $142,198, as compared to $133,088 for the first half of 2015. Our gross profit performance ended at $58,898 or 41% of sales, as compared to $49,771 or 37% of sales for the comparable prior period.

With respect to specific categories, sales for our Crop business were $119,605, up approximately 2% from $117,313 in 2015, while sales for Non-crop products were $22,593, up by about 43% from $15,775 in the comparable period of the prior year. A more detailed discussion of general market conditions and sales performance by category of products appears below.

Over the course of the first half of 2016, the Company experienced a more stable demand for its corn products notwithstanding continued actions in the Midwest channel of distribution to work through some remaining surplus inventories and generally lower commodity prices driving growers to consider options for reducing per acre input costs. Our 6-month sales of soil insecticides increased and sales of Impact® herbicide increased by 40% year-over-year, reflecting grower efforts to maximize yields and lower channel inventory. While half-year sales of our primary cotton products currently trail the prior year, our 2016 sales have benefited from several 2015 herbicide product acquisitions which include Scepter, our first US soybean herbicide.

Net sales of our Insecticides used in crop applications for the six months ended June 30, 2016 were about 3% higher at $64,018, as compared to $61,945 during the first half of 2015. Within this category, sales of our granular soil insecticides (“GSIs”) were up approximately 4% relative to the comparable period in 2015. Demand for our Thimet product has been strong and sales of our granular insecticides Mocap and Nemacur, sold primarily in our international markets, were stronger than the prior year. Sales of our non-GSI insecticides for crop applications were flat during the first half of 2016, as compared to the same period of the prior year.

Within the group of Herbicides/Fungicides/Fumigants for crop applications, sales for the first half of 2016 were $45,767, approximately 16% higher than the $39,291 recorded in the first half of 2015. While sales of our soil fumigant products declined moderately as a result of some weather-related wet field application difficulties, sales of herbicides increased significantly during the first half of the year driven by strong Impact sales in U.S. corn and the addition of new Bromacil and Scepter product acquisitions.

Within the group of Other products (which includes plant growth regulators, molluscicides and tolling activity), we recorded net sales of $9,820, as compared to $16,077 in the first half of 2015. More than half of this decline resulted from lower international toll manufacturing revenues in the first six months of 2016 as a result of a shift in our manufacturing schedule, which was advantageous to both the Company and our customer. Additionally, sales of our cotton harvest aid, Folex, were lower than the prior year as our customers delayed many second quarter purchases until the third quarter of this year, just-in-time for use as a pre-harvest defoliant.

Our Non-crop sales for the first half of 2016 were $22,593, up 43% from $15,775 for the same period of the prior year. This performance was driven by our Pest Strip business, pharmaceutical and Envance sales that were all considerably higher in the first six months of 2016, as compared to the similar period in 2015.

On a regional basis, our domestic US sales improved by 9% to end at $101,628 for the first half of 2016, as compared to $93,064 in the same period of 2015. During the same period, our international sales were up 1% to end at $40,570, as compared to $40,024 for the prior year. Our International year-over-year sales growth is mainly related to the Nemacur and Bromacil acquisitions from last year. Both acquisitions have now been fully integrated in our existing business. In fact, our herbicides increased more than twofold driven by the Bromacil product line. Our granular insecticide products were up 6% overall, with Nemacur up 16%, primarily the result of the 2015 acquisition of the European registrations. The remainder of our granular product sales were balanced with strong sales of Thimet and Mocap offset by slower Counter sales. Offsetting these positives and as noted above, our international tolling revenues were delayed in 2016, as compared with 2015.

Our cost of sales for the first half of 2016 was $83,300 or 59% of net sales. This compared to $83,317 or 63% of net sales for the same period of 2015. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales.

The raw materials content of cost of sales remained flat as a percentage of sales, with savings on raw materials offset by product mix differences between the first six months of 2016 and the same period of last year.

Our labor and burden costs remained well controlled and were 9% lower in the six months ended June 30, 2016, as compared to the same period of the prior year. Further, as our channel inventories have reduced and as we have been slowly ramping up production of some products, factory activity and associated factory cost recovery increased by 8%, as compared to the first six months of 2015. These improvements resulted in lower unabsorbed factory overhead costs which amounted to 5% (of sales) in the first half of 2016, as compared to 7% in the same period of 2015 and added $2,958 to our gross profit performance in the first half of 2016, as compared to this time last year.

It should be noted that, when making comparisons with other companies’ financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

Operating expenses increased by $908 to $49,174 for the six months ended June 30, 2016, as compared to $48,266 for the same period in 2015. The differences in operating expenses by department are as follows:

|  | 2016 | 2015 | Change |
| --- | ---: | ---: | ---: |
| Selling | $12,704 | $14,309 | $(1,605) |
| General and administrative | 15,718 | 13,410 | 2,308 |
| Research, product development and regulatory | 10,622 | 10,112 | 510 |
| Freight, delivery and warehousing | 10,130 | 10,435 | (305) |
|  | $49,174 | $48,266 | $908 |

- Selling expenses for the period decreased by $1,605 to end at $12,704, as compared to the first six months of 2015. The main drivers for the overall decrease in selling expenses were lower spending on advertising and promotional activities.
- General and administrative expenses increased by $2,308 to end at $15,718, as compared to $13,410 for the same period of 2015. The main drivers for the increase are increases in incentive compensation, increases in intangible asset amortization associated with product acquisitions in 2015 and additional legal expenses.
- Research, product development costs and regulatory expenses increased by $510 to end at $10,622, as compared to $10,112 for the same period of the prior year. The main driver was increased costs incurred in our regulatory affairs activities.
- Freight, delivery and warehousing costs for the six months ended June 30, 2016 were $10,130 or 7.1% of sales as compared to $10,435 or 7.8% of sales for the same period in 2015. The main driver for the decrease is related to the increase in sales of products with low freight costs and products where buyers bear freight charges.

Interest costs, net of capitalized interest, were $1,003 in the six months of 2016, as compared to $1,303 in the same period of 2015. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Six months ended June 30, 2016 Average Debt | Interest Expense | Interest Rate | Six months ended June 30, 2015 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Average revolving line of credit | $73,852 | $857 | 2.3% | $106,120 | $1,043 | 2.0% |
| Notes payable | 35 | 1 | — | 851 | 69 | — |
| Interest income | — | (1) | — | — | (1) | — |
| Amortization of deferred loan fees | — | 125 | — | — | 166 | — |
| Amortization of other deferred liabilities | — | 19 | — | — | 85 | — |
| Other interest expense | — | 25 | — | — | 28 | — |
| Subtotal | $73,887 | $1,026 | 2.8% | $106,971 | $1,390 | 2.5% |
| Capitalized interest | — | (23) | — | — | (87) | — |
| Total | $73,887 | $1,003 | 2.7% | $106,971 | $1,303 | 2.4% |

The Company’s average overall debt for the six months ended June 30, 2016 was $73,887, as compared to $106,971 for the six months ended June 30, 2015. During the six months ended June 30, 2016, we remained focused on driving down our revolving debt following the 2015 product acquisitions. As can be seen from the table above, our effective bank interest rate was 2.7% for the six months ended June 30, 2016 as compared to 2.4% for the same period in 2015.

Income tax expense was $2,263 for the six months ended June 30, 2016, as compared to a benefit of $685 for the comparable period in 2015. The effective tax rate for the first half of the year was 25.9% (which was an expense), as compared to 339.1% (which was a tax benefit), in the same period of the prior year. The change in effective tax rate is primarily driven by improved year on year financial performance in jurisdictions with higher tax rates.

Furthermore, the effective tax rate for the six months ended June 30, 2016, is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

Our net income for the first six months of 2016 was $6,040 or $0.21 per basic and diluted share, as compared to $832 or $0.03 per basic and diluted share in the same period of 2015.

### LIQUIDITY AND CAPITAL RESOURCES

The Company generated $25,490 of cash from operating activities during the six months ended June 30, 2016. This compared with generating $43,824 in the same period of the prior year. Net income of $6,329, the sum of non-cash depreciation and amortization of fixed and intangible assets, other assets and discounted future liabilities equaled $10,736 and stock based compensation and other non-cash items of $1,150 provided a net cash inflow $18,215, as compared to $14,117 for the same period last year.

During the six months ended June 30, 2016, the Company increased trade receivables by $4,156. This compares with a decrease in trade receivables of $8,975 during the same period of 2015. The movement in receivables is primarily driven by strong domestic sales in the later part of the period to June 30, 2016.

At the end of June 2016, our inventories were at $151,102, which was down $14,132 from $165,234 at this time last year. In comparison to the start of the financial year, our inventories have increased by $14,625 in the six month period of 2016, as compared to decreasing by $397 during the same period of the prior year. This 2016 performance reflects the improving condition of channel inventory levels of the Company’s products which is allowing us to start slowly increasing the manufacturing level for some products as we look forward to the 2016-2017 season. As of the balance sheet date, June 30, 2016, we believe our inventories are valued at lower of cost or market.

During the six months ended June 30, 2016, deferred revenues decreased by $1,932, as compared to an increase of $3,611 for the same period of the prior year. The decrease in deferred revenues reflects customers utilizing their prepayments made in prior period.

The Company accrues programs in line with the growing season upon which specific products are targeted. Typically, crop products have a growing season that ends on September 30th each year. During the six months ended June 30, 2016, the Company made accruals in the amount of $30,345. Programs are primarily paid out to customers either in the final quarter of the fiscal year or the first quarter of the next fiscal year. However, there are some programs that are paid more frequently or that have different settlement dates that reflect particular growing seasons. During the first six months of 2016, the Company made payments in the amount of $12,389. Payments are not generally significant in the second and third quarters of each financial year. During the six months ended June 30, 2015, the Company accrued $25,673 and made payments in the amount of $8,616.

Finally, prepaid and other assets increased by $2,661, tax receivable decreased by $1,244, accounts payable increased by $9,837, and other payables and accruals increased by $1,612. In aggregate, this amounted to a $10,032 inflow. During the same period of 2015, these items amounted to a $333 outflow.

The Company is working to manage its capital spending closely and utilized $1,729 during the six months ended June 30, 2016, compared to utilizing $3,480 during the same period of 2015. This is primarily driven by lower capital spending in our factories. During the first six months of 2016, the Company made an equity investment in Biological Products for Agriculture (“Bi-PA”) through its Netherlands wholly-owned subsidiary. Bi-PA develops biological plant protection products that can be used for the control of pests and disease of agricultural crops. As of June 30, 2016, the Company’s ownership position in Bi-PA was 15%. During the comparable period in 2015, the Company increased its ownership share of its Envance subsidiary by paying $125 to its joint venture partner, TyraTech. Finally, during the first six months of 2015, the Company completed two acquisitions of product lines and spent a total of $36,435 on those transactions. During the first six months of 2016, the Company made final payments associated with the 2015 product acquisitions in the amount of $224.

Financing activities used $19,455 during the six months ended June 30, 2016, compared to $3,193 in the same period of the prior year. This 2016 performance was mainly driven by the Company’s efforts to drive down debt on our senior credit facility.

The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at June 30, 2016 and December 31, 2015. These are summarized in the following table:

| Indebtedness $000’s | June 30, 2016 Long- term | Short- term | Total | December 31, 2015 Long- term | Short- term | Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit | $50,150 | $— | $50,150 | $69,000 | $— | $69,000 |
| Deferred loan fees | (574) | — | (574) | (679) | — | (679) |
| Notes payable | — | 18 | 18 | — | 55 | 55 |
| Total Indebtedness | $49,576 | $18 | $49,594 | $68,321 | $55 | $68,376 |

The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio (taking into account the Company’s twelve month trailing EBITDA), (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of June 30, 2016 the Company met all covenants in that credit facility.

At June 30, 2016, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $92,588 under the credit facility agreement. This compares to an available borrowing capacity of $27,101 as of June 30, 2015. The increased level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for the trailing twelve month period, has improved, (2) borrowings have decreased compared to the second quarter of 2015, when the Company had borrowed from the credit facility to fund two product line acquisitions, and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement) is lower when compared with the earlier period.

The Company believes that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

### RECENTLY ISSUED ACCOUNTING GUIDANCE

Recently Issued Accounting Guidance—In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, *Compensation—Stock Compensation (Topic 718)*. The new standard changes the accounting for certain aspects of share-based payments to employees. The standard requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital (“APIC”) pools. The standard also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. Cash paid by an employer when directly withholding shares for tax-withholding purposes should be classified as a financing activity in the statement of cash flows. In addition, the standard allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The new standard is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In March 2016, FASB issued ASU 2016-07, *Investments—Equity Method and Joint Ventures*. The new standard eliminates the requirement that an investor retrospectively apply equity method accounting when an investment that it had accounted for by another method initially qualifies for the equity method. The guidance requires that an equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor’s previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The new standard is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In February 2016, FASB issued ASU 2016-02, *Leases*. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In January 2016, FASB issued ASU 2016-01, *Recognition and Measurement of Financial Assets and Financial Liabilities*. The update provides that equity investments with readily determinable values be measured at fair value and changes in the fair value flow through net income. These changes historically have run through other comprehensive income. Equity investments without readily determinable fair values have the option to be measured at fair value or at cost adjusted for changes in observable prices minus impairment. Changes in either method are also recognized in net income. The standard requires a qualitative assessment of impairment indicators at each reporting period. For financial liabilities, entities that elect the fair value option must recognize the change in fair value attributable to instrument-specific credit risk in other comprehensive income rather than net income. Lastly, regarding deferred tax assets, the need for a valuation allowance on a deferred tax asset will need to be assessed related to available-for-sale debt securities. The guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Earlier adoption is permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In November 2015, FASB issued ASU 2015-17, *Balance Sheet Classification of Deferred Taxes.* The standard requires all deferred tax assets and liabilities, as well as any related valuation allowance, to be classified as non-current on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and earlier adoption is permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In July 2015, FASB issued ASU 2015-11, *Inventory (Topic 330)*. Topic 330 currently requires an entity to measure inventory at the lower of cost or market, where market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. This ASU limits the scope to inventory that is measured using first-in, first-out (FIFO) or average cost and requires inventory be measured at the lower of costs or net realizable value. The new standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In August 2014, FASB issued ASU 2014-15, *Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.* This ASU requires that management of an entity assesses whether there is substantial doubt about the ability of the entity to continue as a going concern and for making the appropriate disclosures. The assessment must be performed at each annual and interim reporting period, and there is substantial doubt about an entity’s ability to continue as a going concern if it is probable that the entity will be unable to meet its obligations as they become due within 12 months of the date the financial statements are issued. In the assessment, management must consider the information available at the date of issuance of the financial statements, as well as mitigating factors and plans to alleviate the substantial doubt. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods thereafter. Early application is permitted. Upon adoption, the Company will follow the guidance in this ASU when assessing going concern.

In May 2014, FASB issued ASU 2014-09, *Revenue from Contracts with Customers*. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. In March 2016, FASB issued an amendment to the standard, ASU 2016-08, to clarify the implementation guidance on principal versus agent considerations. Under the amendment, an entity is required to determine whether the nature of its promise is to provide the specified good or service itself (that is, the entity is a principal) or to arrange for that good or service to be provided by the other party (that is, the entity is an agent). In April 2016, FASB issued another amendment to the standard, ASU 2016-10, to clarify identifying performance obligations and the licensing implementation guidance, which retaining the related principles for those areas. The standard and the amendments are effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of its pending adoption of ASU 2014-09 on the consolidated financial statements and has not yet determined the method by which it will adopt the standard in 2017 or its impact on the consolidated financial statements.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements for inclusion in the American Vanguard published financial statements. In the Company’s Form 10-K for the financial year ended December 31, 2015, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2015.

## Market risk

As filed, 1,252 characters.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2015.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

## Controls and procedures

As filed, 1,064 characters.

As of June 30, 2016, the Company established a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of June 30, 2016, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

### PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

## Risk factors

As filed, 406 characters.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2015, filed on March 2, 2016. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors.

Filed Aug 2, 2016.
Source: SEC EDGAR, the filing index for accession 0001193125-16-668296. Last ingested by Listed: Nov 11, 2026, 00:16 ET. No prices; not investment advice.
